Pfizer will now employ Novavax’s adjuvant, Matrix-M, into its vaccines across two disease areas.

By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

Earlier in January 2026, Novavax announced a non-exclusive license and option agreement granting Pfizer worldwide rights to ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

Novavax ‌said on ‌Tuesday it was ⁠entering ‌into a ‍licensing agreement with ​Pfizer ‌to develop vaccine products ⁠for ...

Gaithersburg’s Novavax has struck a deal to give Pfizer the rights to its adjuvant technology — for a potential $530 million ...

Novavax (NVAX) shares added ~5% in the premarket on Tuesday after the COVID-19 vaccine maker reached a licensing deal with ...

Novavax has agreed to a deal to let Pfizer use Matrix-M adjuvant in its products for an upfront payment of $30 million and up to another $500 million in milestone payments.

Novavax, the Covid-19 vaccine maker, has licensed the rights for a vaccine-enhancing component to Pfizer. Pfizer agreed to pay $30 million upfront, and could pay up to $500 million more if development ...

The Food and Drug Administration authorized Novavax's single-strain vaccine, which targets omicron subvariant XBB.1.5, for emergency use in people ages 12 and up. The Centers for Disease Control and ...

Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while ...